Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
IPO Year:
Exchange: NYSE
Website: novartis.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/11/2024 | $135.00 → $130.00 | Buy → Neutral | BofA Securities |
| 9/5/2024 | Buy → Neutral | Goldman | |
| 9/3/2024 | Buy → Hold | Jefferies | |
| 7/19/2024 | Buy → Hold | Deutsche Bank | |
| 5/30/2024 | $120.00 | Buy | Goldman |
| 2/23/2024 | $114.00 | Market Perform | BMO Capital Markets |
| 1/23/2024 | $114.00 | Equal-Weight | Morgan Stanley |
| 1/16/2024 | Buy | UBS | |
| 12/18/2023 | Buy → Hold | HSBC Securities | |
| 9/25/2023 | Underweight → Equal-Weight | Morgan Stanley |
BofA Securities downgraded Novartis AG from Buy to Neutral and set a new price target of $130.00 from $135.00 previously
Goldman downgraded Novartis AG from Buy to Neutral
Jefferies downgraded Novartis AG from Buy to Hold
Deutsche Bank downgraded Novartis AG from Buy to Hold
Goldman initiated coverage of Novartis AG with a rating of Buy and set a new price target of $120.00
BMO Capital Markets initiated coverage of Novartis AG with a rating of Market Perform and set a new price target of $114.00
Morgan Stanley initiated coverage of Novartis AG with a rating of Equal-Weight and set a new price target of $114.00
UBS resumed coverage of Novartis AG with a rating of Buy
HSBC Securities downgraded Novartis AG from Buy to Hold
Morgan Stanley upgraded Novartis AG from Underweight to Equal-Weight
For Immediate Release: November 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA published the FDA Voices: “FDA Takes Exciting Steps Toward Establishing the Rare Disease Innovation Hub,” by Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER) and Peter Marks, M.D., Ph.D., director
SC 13D/A - NOVARTIS AG (0001114448) (Filed by)
6-K - NOVARTIS AG (0001114448) (Filer)
6-K - NOVARTIS AG (0001114448) (Filer)
6-K - NOVARTIS AG (0001114448) (Filer)
6-K - NOVARTIS AG (0001114448) (Filer)
FWP - NOVARTIS AG (0001114448) (Subject)
6-K - NOVARTIS AG (0001114448) (Filer)
6-K - NOVARTIS AG (0001114448) (Filer)
SD - NOVARTIS AG (0001114448) (Filer)
6-K - NOVARTIS AG (0001114448) (Filer)
S-8 POS - NOVARTIS AG (0001114448) (Filer)
Ratio to receive upfront, and potential milestones and tiered royalty payments BOSTON, Nov. 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE:NVS). The collaboration leverages Ratio's radioligand therapy discovery and development expertise as well as its technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer.
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme
Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment with Kisqali® (ribociclib) in combination with an aromatase inhibitor1Recommendation is based on the Phase III NATALEE trial, where Kisqali added to endocrine therapy (ET) significantly reduced the risk of recurrence by 25% versus ET alone across a broad population of patients with HR+/HER2- early breast cancer 2People with stage II or III HR+/HER2- EBC face significant risk of recurrence – often as incurable metastatic disease – despite adjuvant ET and regardless of nodal involvement3,4In Sept
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 3, 2024 /PRNewswire/ -- Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address unmet medical needs. This strategic approach holds promise for providing hope to millions of patients suffering from historically challenging diseases. Alzheimer's disease (AD) for example, has become a focal point of this innovation, with recent U.S. Food and Drug Administration (FDA) approvals of Leqembi and Kisunla — although these treatments only slow cognitive decline rather than improve cognitive function. New uses for approved glucagon-like pept
Potential total transaction valued at more than $1 billion with $65 million in total upfront consideration Generate:Biomedicines ("Generate") today announced a multi-target collaboration with Novartis (NYSE:NVS) to discover and develop protein therapeutics across multiple disease areas. The collaboration leverages Generate's proprietary generative AI platform, "The Generate Platform," to create potentially first- and best-in-class molecules through AI-based optimization and de novo generation. The collaboration will combine The Generate Platform, which integrates machine learning with high-throughput experimental validation, with Novartis expertise and capabilities in target biology, biol
USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 19, 2024 /PRNewswire/ -- USA News Group – In the oncology world, there's been plenty to celebrate recently, with cancer deaths falling by 33% in the last 30 years. However, there's still a lot of work to do in the war on cancer, with the 2024 World Cancer Congress in Geneva highlighting several issues, such as artificial intelligence (AI), conflict zones and crisis care taking center stage at the gathering. Plenty of support for research continues to roll in, with philanthropists recently giving a historic $150 million for pancreatic cancer research to City of Hope, while Stanford experts are calling fo
LEXINGTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that Novartis AG (NYSE:NVS) has agreed to license a novel capsid generated from Voyager's TRACER™ capsid discovery platform for use in a gene therapy program against an undisclosed rare neurologic disease target. This capsid license is being granted pursuant to the agreement between Voyager and Novartis originally announced in March 2022. "Novartis is a global leader in gene therapy, and we view their continued selection of our IV-delivered, blood-brain barrier-penetrant capsids as strong validation of our TRA
Novartis secures exclusive global rights across multiple biologic targets to Lindy Biosciences' microglassification technology Collaboration aims to enable high-concentration self-administered drug treatments, improving patient outcomes and compliance Lindy Biosciences to receive an upfront payment of US$20 million and eligible to receive up to US$934 million in milestone payments plus tiered royalties Lindy Biosciences, a pioneering biotechnology company specializing in innovative drug formulation and delivery technologies, today announced a multi-target exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE:NVS
JUST - EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULESJUST - EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS DEPENDENT ON SUCCESSFUL DEVELOPMENT PROGRESS OF US$ 640 M, ADDITIONAL UNDISCLOSED PAYMENTS DEPENDENT ON PROGRESS INTO COMMERCIAL MANUFACTURING AND EXERCISING THE S.POD OPTIONTHE PARTNERSHIP ASPIRES TO DISRUPT THE BIOSIMILARS MARKET WITH AFFORDABLE AND ACCESSIBLE HIGHEST-QUALITY MEDICINES FOR PATIENTS ACROSS THE GLOBETHE PARTNERSHIP IS FOUNDED ON JUST - EVOTEC BIOLOGICS' AI-DRIVEN, FULLY INTEGRATED TECH PLATFORM AND CONTINUOUS MANUFACTURING COMBINED WITH SANDOZ' LEADING BIOSIMILARS PIPELINE AND CAP
2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst
Concurrent $100 million equity offering Naporafenib has a potential first-in-class and best-in-class profile in multiple RAS/MAPK pathway-driven tumors Pivotal-ready asset has been dosed in over 500 patients to date and expands Erasca's addressable population Erasca to host conference call and webcast today at 8:30 am ET SAN DIEGO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced it has entered into an exclusive worldwide license agreement with Novartis (NYSE:NVS) for naporafenib, a Phase
License option agreement with Novartis for target-specific access to TRACER™ next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets Novartis agreement marks second recent major transaction to leverage Voyager's TRACER technology following October 2021 Pfizer agreement Strengthened leadership with appointment of Al Sandrock, Jr., M.D., Ph.D., to Board of Directors and Board Executive Committee, promotion of Robin Swartz to chief operating officer Cash runway extended into 2024 with $84 million aggregate upfront payments from Novartis and Pfizer transactions Conference call and webcast today at 8:30 a.m. ET
Voyager receives $54 million upfront with potential option exercise fees and milestone payments of up to $1.7 billion plus product sales-based royalties Novartis receives target-specific access to Voyager's novel TRACER AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets Agreement marks the second recent major transaction leveraging Voyager's TRACER capsid discovery platform Conference call and webcast today at 8:30 a.m. ET CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) cap
Moderna COVID-19 Vaccine mRNA-1273: Final blinded analysis of Phase 3 COVE study shows 93% efficacy; Efficacy remains durable through six months after second dose Moderna booster candidates demonstrate robust antibody responses to COVID-19 variants of concern in Phase 2 Dosing started in Phase 1 studies for quadrivalent seasonal flu vaccine candidate (mRNA-1010) and IL-2 mRNA program for autoimmune disorders (mRNA-6231) Moderna has mRNA candidates in clinical development across five therapeutic areas: infectious disease, cardiovascular, oncology, rare disease and autoimmune disorders Q2 total revenue of $4.4 billion, net income of $2.8 billion and diluted earnings per share of $6.46
– Collaboration combines Dren's targeted cell depletion platform with Novartis research, development and commercial expertise to advance innovative therapies for cancer –– Dren Bio to receive total upfront consideration of $150 million and is eligible to receive milestone payments and tiered royalties –Dren Bio, Inc. ("Dren Bio" or the "Company"), a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune, and other serious diseases, today announced that it has entered into a strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE:NVS). The collaboration will focus on the discovery and development of therapeut
Despite the growing tension between China and the United States, worldwide pharmaceutical powerhouses are actively pursuing deals in China. The aim is to strengthen their drug pipelines and expand their presence in the world’s second-largest pharmaceutical market. What Happened: Several significant deals have been signed this year. Notably, AstraZeneca (NASDAQ:AZN) bought China-based cell therapy developer Gracell Biotechnologies for $1.2 billion, and Novartis (NYSE:NVS) acquired the remaining shares of kidney disease therapy developer SanReno Therapeutics for an undisclosed sum, Reuters reported on Tuesday. Bristol Myers Squibb (NYSE:BMY) and Sanofi (NASDAQ:SNY) are also reportedly sc
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels last seen in late April. Both the S&P 500 and the Nasdaq 100 indices declined by 0.6%, while the Dow Jones Industrial Average fell 0.7%, potentially ending a streak of six consecutive positive sessions. Small-cap stocks also succumbed to the broader negative sentiment, with the Russell 2000 index dropping 0.7%. Chicago Fed President Austan Goolsbee, a known “dove” on the board, expressed optimism about progress on inflation and the U.S. economy’s resilience in avoiding a recession. He
Swiss pharma giant Novartis AG (NYSE:NVS) reported a second-quarter adjusted EPS of $1.97, up 21% year over year (+17% on constant currency), beating the consensus of $1.89. The company’s sales reached $12.51 billion, up 11% year over year and 9% in constant currency, beating the consensus of $12.375 billion. Also Read: FDA Approves Novartis’ Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors. Sales growth is driven by a strong performance from Entresto, Kesimpta, Cosentyx, Kisqali, Leqvio, and Pluvicto. The volume contributes 15 percentage points to growth. Generic competition had a negative impact of 2 percentage points, and pric
Beaten-down stocks could make a comeback on Thursday, with Taiwan Semiconductor Manufacturing Company Ltd.’s (NYSE:TSM) strong quarterly report lifting sentiment toward tech stocks. The major U.S. index futures were mixed ahead of the trading session. A few Fed speeches scheduled for the day, and key economic data, including jobless claims, the results of a regional manufacturing survey, and leading economic index may influence trading direction. Traders may also pay attention to the European Central Bank’s rate decision and its monetary policy outlook. FuturesPerformance (+/-)Nasdaq 100+0.40%S&P 500+0.15%Dow-0.13%R2K-0.03% In premarket trading on Thursday, the SPDR S&P 500 ETF Trus
With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows: Wall Street expects D.R. Horton, Inc. (NYSE:DHI) to report quarterly earnings at $3.77 per share on revenue of $9.77 billion before the opening bell, according to data from Benzinga Pro. D.R. Horton shares gained 0.3% to $158.00 in after-hours trading. Novartis AG (NYSE:NVS) posted upbeat results for its second quarter on Thursday. The company reported quarterly adjusted earnings of $1.97 per share, topping market estimates of $1.89 per share. Its sales came in at $12.512 billion beating expectations of $12.375 billion. Novartis shares rose 0.04% to $1
Novartis (NYSE:NVS) reported quarterly earnings of $1.97 per share which beat the analyst consensus estimate of $1.89 by 4.23 percent. This is a 16.57 percent increase over earnings of $1.69 per share from the same period last year. The company reported quarterly sales of $12.512 billion which beat the analyst consensus estimate of $12.375 billion by 1.11 percent. This is a 9.40 percent increase over sales of $11.437 billion the same period last year.
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T
Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme
Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting– – Completion of enrollment in VERITAC-2 expected in 4Q24 and topline data readout now expected 4Q24/1Q25 – – Received $150 million upon close of ARV-766 license agreement and sale of preclinical AR-V7 program to Novartis; potential for up to an additional $1.01 billion based on achievement of development, regulatory and commercial milestones and future royalties – – Strengthened executive team with the appointm
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut
Cagent Vascular announced today that Brian Walsh has been named Chief Executive Officer by the Cagent Vascular Board of Directors. He has served as Chairman of the Board since March 2018 and will continue in this capacity. Mr. Walsh will succeed Carol Burns as CEO. Mr. Walsh previously served as Head of Carl Zeiss Meditech Cataract Technology from 2018 until 2024. Prior to that, he was President and CEO of IanTECH Medical, Inc. (acquired by Carl Zeiss Meditech AG) and Transcend Medical, Inc which was acquired by Alcon, a division of Novartis Co (NYSE:NVS) at the time. Brian Walsh brings over 25 years of medical device and health care industry experience in Marketing, Sales, and Executive
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for up to $1.01 billion in milestones and royalties under license agreement – – Initiated dosing in a first-in-human Phase 1 clinical trial with ARV-102, the first oral PROTAC® degrader in clinical dev
Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel TRACER™ AAV9- and AAV5-derived capsids Preclinical data to be presented at the ASGCT Annual Meeting to demonstrate reduction of tumor burden with vectorized HER2 antibodies; updated data from GBA1, vTau, SOD1 ALS programs also to be presented Executed license option agreement with Novartis for target-specific access to next-generation TRACER™ AAV capsids Appointed Alfred W. Sandrock, Jr., M.D., Ph.D. as Chief Executive Officer and Board Member Cash runway into 2024 CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) --
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. "I am delighted to welcome Cintia to our leadership team. She brings extensive commercial experience, including in cell and gene therapy, that will be key as we prepare to submit our first BLA for afami-cel this year, and build our commercial capabilities to support the launch of this initial product and future next-gen cell therapies within our MAGE-A4 franchise. Her fresh perspective and leadership abilities will supp
AavantiBio ("the Company"), a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Jenny Marlowe, Ph.D. as Chief Scientific Officer. Dr. Marlowe will be responsible for leading AavantiBio's scientific research and preclinical development. She will also serve as a key member of the company's executive leadership team as AavantiBio seeks to advance its diversified pipeline of gene therapies in areas of significant unmet medical need. Dr. Marlowe brings to AavantiBio nearly 15 years of experience in the biopharmaceutical industry, including extensive experience in molecular biology, drug safety, and nonclinical and t